Introduction
Substantial evidence indicates that underlying immunological mechanismsare important in the pathogenesis of inflammatory bowel disease (IBD). Thus, significant attention has focused on the investigation of local lymphocyte infiltrates in the intestinal mucosa (1, 2) . There is increasing interest in the cytotoxic activity oflamina propria mononuclear cells (LPMC) in IBD under the assumption that the mucosal tissue damage can be mediated by the cytolytic function of the local immune cells. Most types ofcytotoxic cells and their function have been studied using the cells isolated from the IBD-involved mucosa, including natural killer cell activity, antibody-dependent cellular cytotoxicity, antigen specific T cell cytotoxicity, anti-CD3-induced cytotoxicity and lymphokine-activated killer (LAK) cell activity (3) . Amongthese cytotoxic cells, LAKcell activity has been investigated intensively because of its broad activity against the target cells including those of intestinal origin (4) (5) (6) (7) . Theconsistent and reliable nature of cytotoxic mechanisms can be used to reveal abnormalities of intestinal immunereactivity in IBD (7) .
In our previous studies, we found that intestinal LAKcell activity differs among Crohn' s disease (CD), ulcerative colitis (UC) and controls: CD LPMCexhibit greaterlevels ofLAK cell activity whereas UCLPMCdisplay lower levels of activity than control cells (7) . Using the cells isolated from the UC-affected and control mucosa, we also demonstrated that there is a positive correlation between the level of LAKcell activity and the proportion of CD56+lymphocytes in the intestinal mucosa and that the precursor cells responsible for intestinal LAKcell activity may reside in CD56+ lymphocytes (8) . Considering that CD56+ lymphocytes co-express IL-2 receptors (IL-2R) to a higher degree and proliferate well in response to IL-2 (9, 10), the local expansion ofLAKprecursor cells maybe regulated by the level of IL-2 produced in the micro-environment of the intestinal mucosa. In fact, recent studies have demonstrated that mucosal IL-2 mRNAexpression and IL-2 secreting cells are increased in CD but not in UC (1 1, 12) . Therefore, we investigated the number of CD56+lymphocytes, the LAKcell activity, the frequency of LAKprecursor cells, and the expression of the mechanisms involved in the different mucosalimmune response of CDand UCpatients.
Materials and Methods

Study groups
Colonic mucosal tissues were obtained from colonoscopic biopsies (n=12) or surgical specimens (n=5) from 17 patients with CD. The group included 10 men and seven women, ranging from 1 8 to 46 years of age (mean age, 29.4 years). Three patients had disease limited to the colon and 14 had ileocolonic disease. The disease had been present from one month to 13 years. At the time of the study, two patients were receiving prednisolone alone ( 1 0-1 5 mg/day), three were on sulfasalazine alone (3.0 g/day), four were being treated with prednisolone (10-15 mg/day) plus sulfasalazine (3.0 g/day), and eight were receiving no specific drug therapy. Colonic mucosal specimens were also obtained from colonoscopic biopsies (n=14) or surgical specimens (n=2) from 16 patients with UC. Eight were menand eight were women, ranging from 20 to 60 years of age (mean age, 36. 1 years). Ten patients had total colitis, five leftsided colitis, and one proctitis. The disease had been present from one monthto 12 years. One was receiving prednisolone alone (60 mg/day), three were on sulfasalazine alone (3.0 g/ day), eight were being treated with prednisolone (5-30 mg/day) plus sulfasalazine ( 1.5-4.0 g/day), and four were on no specific drug therapy. Control colonic mucosal specimens were obtained from surgical specimens from 18 patients with colonic adenocarcinoma, two with diverticular disease, and one with multiple colonic adenomas. The group was composedof eight men and 13 women, ranging from 22 to 70 years of age (mean age, 55.1 years).
All samples were obtained with informed consent in accordance with the Helsinki Declaration and the diagnoses were confirmed by clinical, radiological, endoscopic and histological criteria.
Isolation of lamina propria mononuclear cells In CDand UCpatients, colonoscopic biopsies or surgical specimens were obtained from the inflamed mucosaof the colon. Mucosal involvement by active inflammation was confirmed histologically in all specimens used in this study. Control colonic mucosa was taken from the histologically normal portion of surgical specimens at least 10 cm apart from the involved sites with the tumor or diverticular disease. All specimens were weighed before isolation procedures of LPMC. The method used to isolate LPMCfrom colonoscopic biopsies or surgical specimens was an enzymatic methodusing collagenase and DNAasefollowed by a Ficoll-Hypaque gradient as described in detail elsewhere (7, 8, 13 Induction of lymphokine-activated killer cell activity and cytotoxic assay
To induce LAK effector cells, freshly isolated LPMCwere incubated at 1 x 106 cells/ml in RPMI 1640 medium (Gibco, Grand Island, NY) with 5% heat-inactivated human AB serum, HEPESbuffer and antibiotics (culture medium) in the presence of 100 U/ml recombinant IL-2 (rIL-2, kindly provided by Takeda Chemical Ind., Osaka) for 96 hours at 37°C in a 5% CO2 incubator.
The cytotoxic assay was performed by a 51Cr release assay using HT-29 cells derived from human colonic carcinoma (kindly provided by Dr. Toshifumi Hibi, Keio University, Tokyo) and a human B lymphoblastoid line, Daudi cells (kindly provided by Japanese Cancer Resources Bank, Tokyo) as previously described (7). Briefly, the target cells were labeled with 100 jiCi 51sodium chromate for 60 minutes. Then, the target cells were washed three times and added (5 x 103 cells) to the wells of the round-bottommicrotiter plates containing various numbers of effector cells (total volume, 200 jlxI).
Microtiter plates were incubated for 4 hours at 37°C in a 5% CO2incubator. At the end of the incubation period, the plates were spun and the radioactivity of the supernatant ( 1 00 jLll) from each well was measured in a y-counter. Cytotoxicity was calculated as the percentage of specific 51Cr release using the following formula: Specific release (%) = (Experimental cpmSpontaneous cpm) / (Maximal cpm -Spontaneous cpm) x 100. The results were expressed in lytic unit (LU) per 107 effector cells required to induce 20%specific 51Cr release from 5 x 103 target cells (14) .
In someexperiments with the surgical specimens, a combination of a modified panning technique and complementmediated lysis was utilized to deplete the cells bearing CD3or CD56 antigens from LPMCprior to incubation with rIL-2 (8).
The contamination of CD3+or CD56+cells in the depleted fractions was less than 3.0% and 0.5%, respectively, as demonstrated by FACS analysis.
Limiting-dilution analysis for lymphokine-activated killer precursor cells A limiting-dilution assay was performed according to the method of Vie et al (15) to determine the frequency of LAK precursor cells among LPMC.Increasing numbers of freshly isolatedLPMC (1 x 103, 5 x 103, 1 x 104, 5 x 104cells/200 jil) were put in the wells of the round-bottom microtiter plates with 100 U/ml rIL-2, with 24-36 wells seeded for each cell concentration. The plates were incubated for 8 days at 37°C in a 5% CO2 incubator. At the end of the incubation period, 5^r-labeled HT-29 cells (5 x 103) were added to each well and cytotoxic tests were performed as described in the preceding paragraph.
Individual wells were classified as positive or negative in reference to the threshold calculated as 3 SD above the mean cpm of control wells. Frequencies were determined using the %2-minimalization method of Taswell ( 1 6).
Analysis of messenger RNAby polymerase chain reaction and dot blot hybridization To obtain mRNA from freshly isolated LPMC,polyadenylated RNAwas directly extracted from cell pellets (2 x 105 cells) using the oligo(dT)-cellulose (Quick Prep Micro mRNAPurification Kit, Pharmacia, Uppsala, Sweden). Extracted mRNA was reverse-transcribed for 1 hour at 42°C with 0.5 jal of Rous-associated virus 2 reverse-transcriptase (Takara Biomedicals, Ohtsu) and 100 pmol of oligo (dT) (Pharmacia) in a 24 |il reaction mixture. Twelvemicrbliters of complementary DNA(CDNA)from each sample were amplified separately with specific 5' and 3' primers for IL-2 and P-actin (200 pmol) in a 100 jil polymerase chain reaction (PCR) mixture containing 0.5 jal of Taq DNApolymerase (Promega Corporation, Madison, WI) withthe cycles of 1 minute at94°C, 1 minute at 60°C and 2 minutes at 72°C in a thermal cycler (Perkin Elmer Cetus, Norwalk, CT). The following oligonucleotide 5' and 3' primers were synthesized using a DNAsynthesizer (Applied Biosystems, Foster City, CA): IL-2, ATGTACAGGATG-CAACTCCTGTCTT and GTCAGTGTTGAGATGATGC-TTTGAC; p-actin, GTGGGGCGCCCCAGGCACCA and CTCCTTAATGTCACGCACGATTTC. The amplified product was electrophoresed in a 2%agarose gel with ethidium bromide and visualized by UVtransillumination.
To quantitate the expression of mRNA for IL-2 and P-actin, dot blot hybridization was performed using the PCR product. Three microliters of amplified CDNA were spotted directly onto a nylon membrane (Amersham International pic , Buckinghamshire, England), denatured with 0.5 mol NaOH, neutralized, and cross-linked by UVlight for 2 minutes. After an overnight prehybridization, the membranewas hybridized for 24 hours at 42°C with 32P-labeled oligonucleotides internal to each amplified product. Radioactive blots were quantitated using an image scanner (Fujix BAS 2000, Fuji Photo Film Co., Tokyo).
Analysis of data
Statistical analysis was performed using the paired t, KruskalWallis, Wilcoxon's rank-sum tests. All data were expressed as mean±SEM.
Results
Cell surface markers The cell surface markers of freshly isolated LPMCwere determined using flow cytometric analysis with a variety of monoclonal antibodies in nine CD, eight UCand nine control patients. Lymphokine-activated killer cell activity and frequency of lymphokine-activated killer precursor cells In the bulk cultures stimulated with 100 U/ml rIL-2 for 96 hours, CD LPMCexhibited significantly (p<0.0 1 ) higher levels of LAKcell activity against colonic carcinoma-derived HT-29 cells, while UC LPMCshowed significantly (p<0.05) lower levels of cytotoxic activity than control LPMC. Almost identical results were obtained whenhumanB lymphoblastoid Daudi cells were used as a target (data not shown). Whenthe frequency of LAKprecursor cells was determined by the limitingdilution analysis, LPMCderived from CD specimens contained more (p<0.05) LAKprecursor cells and those from UC specimens had fewer (p<0.05) cells compared with controls (Table  2) . To determine the phenotypes responsible for LAKcell activity, the cells bearing CD3or CD56antigens were depleted before 96 hour culture with rIL-2. As shown in Table 3 *The surface marker of freshly isolated LPMCwas analyzed by two-color flow cytometry in nine CD, eight UC and nine control patients. fAfter incubation with 100 U/ml rIL-2 for 96 hours, the surface marker of the cultured cells was analyzed by two-color flow cytometry in eight CD, seven
UCand seven control patients.^p<0.05 compared with control. *After incubation with 100 U/ml rIL-2 for 96 hours, LAKcell activity was measured by a 51Cr release assay using HT-29 target cells. +':':A combination of a panning technique and complement-mediated lysis was utilized to deplete the cells bearing CD3or CD56 antigens from LPMCprior to incubation with rIL-2.
2 significantly decreased the cytotoxic activity, whereas depletion of CD3+lymphocytes did not significantly influence the cytotoxicity. These data indicated that both CD3+, CD56+ and CD3~,CD56+lymphocytes comprise the main phenotypes of LAKprecursor cells in the colonic mucosa.
Expression of messenger RNAfor interleukin-2 in lamina propria mononuclearcells
In the preliminary experiments of reverse-transcriptase PCR (RT-PCR) analysis using freshly isolated LPMC, IL-2 CDNA was detected as a band on the ethidium bromide-stained gel from 26 or 28 PCRcycles and saturated in the range over 34 or 36 cycles (Fig. 1, left panel) . In contrast, p-actin CDNAwas detected from 24 or 26 PCRcycles and reached a saturation over 34PCRcycles (Fig. 1 , rightpanel) . Therefore, wechose 30PCR cycles to compare the levels ofIL-2 mRNA expressed in LPMC and amplified all samples at once to avoid the variability between the assays. The original levels of IL-2 mRNA in individual LPMCwere quantitated by the radioactivity ratio of IL-2 to p-actin CDNAin each dot blot (Fig. 2) . When normalized by the level of p-actin mRNA,CDLPMC (n=10) exhibited significantly (p<0.01) higher IL-2 mRNA levels (0.227±0.034) compared with control LPMC (n=10, 0.069±0.028). In contrast, there was no significant difference of IL-2 mRNA levels between UC LPMC (n=8, 0.086+0.021) and control cells.
Experimental data and clinical parameters
There were no significant differences or associations of cell surface markers, LAKcell activity, LAKprecursor cells and expression of IL-2 mRNA with sex and age of the patients, length of disease, anatomical segment of the large bowel and type of drug therapy. 
Frequency of lymphokine-activated killer precursor cells and clinical course
To assess whether LAKcell activity is associated with disease activity (17) , werepeated the limiting-dilution analysis to monitor the frequency of LAKprecursor cells three to six months after introduction of the therapy with total parenteral nutrition or elemental diet in three cases of active CDpatients without any specific drug therapy during the observation period. A substantial decrease was observed in the numberof LAKprecursor cells after nutritional therapy (case 1 : 220 vs 22 per 106cells, case 2: 92vs 42per 106cells, case 3: 67 vs 17per 1 06 cells, before and after therapy, respectively) in parallel with the decrease in disease activity evaluated by the IOIBDscore (case 1: 5 vs0, case2: 4vs 1,case 3: 4vs 0,beforeandafter therapy, respectively).
Discussion
The results of the present study further support the observation that mucosal immunereactivity is different between the two forms of IBD (7 against colon carcinoma HT-29 and Daudi target cells, whereas UC-derived LPMCdisplayed lower cytotoxic activity. Furthermore, the parallel experiments using the limiting-dilution analysis demonstrated that the number of LAKprecursor cells was correlated with the cytotoxic activity in the bulk culture, suggesting that the differences in LAKcell activity among CD, UC and control LPMCcan be attributed to the alteration in the number ofLAKprecursor cells. This study also showed that IL-2 mRNAexpression was increased in CD LPMC,but not in UC LPMC,which may be responsible for the increased number of IL-2-responsive LAKprecursor cells in the intestinal mucosa affected with CD (9). The mechanismsofLAKcell development and lytic activity in the intestine has not been clearly defined. Earlier studies using peripheral blood have shown that the majority of LAK cell activity is derived from both CD3+, CD56+ T lymphocytes and CD3~, CD56+NK cells which comprise the cells capable of mediating non-MHC restricted cytotoxicity (18) . Previously, using depletion and enrichment experiments with control LPMC, we found that the precursor cells responsible for intestinal LAK cell activity are also restricted to these two distinct subpopulations (8, 10) . Consistent with this observation, the depletion experiment in the present study demonstrated that lamina propria CD56+lymphocytes are also the main precursors for LAKcell activity in the IBD-affected mucosa. However, since the number of CD56+lymphocytes was muchhigher than that of LAK precursor cells obtained in the limiting-dilution analysis, LAK precursor cells may be present as a small subpopulation among lamina propria CD56+ lymphocytes. In this study CD-derived LPMCcontained more CD56+ lymphocytes, especially CD3+, CD56+lymphocytes, and UC-derived LPMChad fewer CD3+, CD56+and CD3~, CD56+lymphocytes compared with control cells, when freshly isolated LPMCwere analyzed in the flow cytometry. Van Tol et al also demonstrated that non-MHC restricted cytotoxicity mediated by CD56+ lymphocytes was increased in CD LPMCcompared with UC LPMC (19) . Taken together, the numerical alteration in LAKprecursors among mRNAwas enhanced in freshly isolated LPMCfrom the inflamed mucosa with CDthan in control LPMCbut there was no significant difference in IL-2 mRNA levels between the cells from the diseased mucosa with UCand control cells. Recently, Mullin et al showed that IL-2 mRNA was increased in the whole biopsy tissues from the inflamed mucosa with CDbut not in the tissues from the mucosa with UC (1 1, 20) . Using the reverse hemolytic plaque assay of isolated LPMC,Breese et al demonstrated that IL-2 secreting cells were readily detectable in the mucosa involved with CDwhereas they were mostly absent or present atonly low levels inthe mucosa with UC (12) . Together, these findings strongly suggest that functional heterogeneity of mucosal helper T cells may contribute to the difference ofLAK cell activity between these two forms of IBD. Since IL-2 is a pivotal cytokine for the proliferation of LAKprecursor cells possessing IL-2R (7, 9) , enhanced production of endogenous IL-2 may be involved in the increased number of CD56+ LAK precursor cells in the mucosa with CD(7). This concept is further strengthened by the observation in this study that there was a prominent increase of CD56+cells, especially CD3+, CD56+cells in CDLPMCafter in vitro culture with exogenous rIL-2. On the other hand, the number of LAKprecursor cells was decreased in UCLPMCcompared with control cells in spite of comparable levels of IL-2 mRNA expression. The reason for this observation is not clear, but it may be due to compartmentalization or altered homing patterns of LAKprecursor cells as described in other intestinal lymphoid cells (21 , 22) or limited responsiveness of LAKprecursor cells to IL-2. The last hypothesis is most likely because in this study UC LPMCexhibited a restricted expansion of CD3+, CD56+cells even in the presence of an optimal concentration of rIL-2 (7). The differential expression of IL-2 between CD and UC LPMCmay be explained by a selective activation or proportional shift of mucosa helper T cell subsets. In the murine models, helper T cells are divided into T helper cells type-1 (Thl), marked by the production of IL-2 and IFN-y, and T helper cells type-2 (Th2), marked by the production ofIL-4, IL-5, IL-6 and IL-10 (23). In the murine parasitic infection, a differential activation of Thl or Th2 cells is associated with a resistance or susceptibility to the parasitic agents (24, 25) . The involvement of T helper subsets was also suggested by Yamamuraet al in the study of humanleprosy lesions in which the selected expression ofThl or Th2 cytokines is critical to the formation of the characteristic disease, tuberculoid or lepromatous lesions, respectively (26) . Since the proportion of cells positive for the conventional cell surface marker for helper T cells (CD4+, 2H4" cells) was similar between CD and UC LPMC (8, 27) , the future development of cell surface markers which distinguish Thl and Th2-like cells will clarify whether abnormalities of mucosal helper T cell subsets are associated with the pathogenesis of IBD (20) . Increasing evidence suggests the involvement of T cells in the pathogenesis of CD. These include elevated IL-2 and soluble IL-2R levels in the serum of the patients with CD (28, 29) , the benefit ofcyclosporine for the treatment of CD(30), the remission of CD associated with the onset of the human immunodeficiency virus infection which affects CD4+T helper cells (3 1), and symptomatic exacerbation in patients with CD after infusion of high-dose IL-2 for the treatment of associated malignany (32) . However, in regard to mucosal T cells, little is knownabout the role in the immuneeffector function in the inflamed mucosa with CD. The data of the present study demonstrate that a subset of mucosal T cells with CD56 antigens could mediate substantial levels of LAKcell activity as a predominant phenotype in the patients with CD. Considering its broad action against mucosal target cells including epithelial and stromal cells (7, 33) , these results suggest that mucosal T cells maybe involved in the tissue damage and resultant inflammatory responses in the patients with CD.
In summary,this study suggests that LPMC express and respond to IL-2 differently in CDand UC. A detailed investigation of mucosal helper T cell subsets can provide important clues for the clarification of the pathogenesis of IBD.
